26th week of 2021 patent applcation highlights part 9 |
Patent application number | Title | Published |
20210196625 | LIQUID NALOXONE SPRAY - The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention. | 2021-07-01 |
20210196626 | OPHTHALMIC DRUG DELIVERY DEVICE AND METHOD FOR FABRICATING THE SAME - An ophthalmic drug delivery device and a method for fabricating the same are provided. The ophthalmic drug delivery device includes a shield element and a drug release element. The shield element has a light transmittance more than or equal to 80%. The drug release element is an annular body so that the drug release element surrounds the shield element. The drug release element is neutral and includes a cross-linked neutral collagen, a first hydrophilic biodegradable polymer and a drug. The shield element is acidic and includes a cross-linked acidic collagen and a second hydrophilic biodegradable polymer. | 2021-07-01 |
20210196627 | SYSTEMS FOR ENTERIC DELIVERY OF THERAPEUTIC AGENTS - Described herein are systems for the enteric delivery of therapeutic agents, and methods of administering a therapeutic agent to a patient by orally administering an enteric delivery system. The enteric deliver system includes one or more carrier members comprising a carrier polymer and a therapeutic agent, and the system is configurable in a compacted configuration and an expanded configuration, and is sized to maintain contact with the intestinal wall of the small intestine by applying an outwardly directed pressure to the intestinal wall and transport at least a portion of the therapeutic agent across the enteric mucosa of the small intestine. | 2021-07-01 |
20210196628 | OPHTHALMIC EMULSION - The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface. | 2021-07-01 |
20210196629 | CANNABINOID BASED EMULSION SYSTEMS FOR INFUSED AQUEOUS COMPOSITIONS - The present disclosure relates to a cannabinoid based emulsification system for infusing an aqueous composition with a cannabinoid, the emulsification system comprising: a) a cannabinoid in a carrier oil; b) a plurality of emulsifiers having a targeted combined HLB value; and c) a targeted plurality of emulsifiers to oil ratio; wherein b) and c) operate to solubilize at least 1 mg of the cannabinoid in 1 mL of an aqueous composition. Methods of making and using such emulsification systems, and cannabinoid concentrate compositions and | 2021-07-01 |
20210196630 | MULTICOMPARTMENT SYSTEM OF NANOCAPSULE-IN-NANOCAPSULE TYPE, FOR ENCAPSULATION OF A LIPOPHILIC AND HYDROPHILIC COMPOUND, AND THE RELATED PRODUCTION METHOD - A multicompartment system of nanocapsule-in-nanocapsule type based on hyaluronic acid derivative is designed for encapsulation of peptides and/or hydrophobic active compounds, either simultaneously or separately, where surfactants, emulsifiers and/or stabilizers are not required for the system stability. The system functions as a carrier which enables protection of sensitive hydrophilic substances against aggressive external environment, and the resulting degradation and deactivation, and makes it possible to concurrently administer active substances of varied hydrophilicity. A method is provided of producing a multicompartment nanocapsule-in-nanocapsule system in the form of water-in-oil-in-water double emulsion. | 2021-07-01 |
20210196631 | CONTAINER SYSTEM AND PHARMACEUTICAL FOAM COMPOSITION COMPRISING BETAMETHASONE - The present invention relates to a pharmaceutical foam composition comprising a corticosteroid and a Vitamin D analogue for topical administration to a patient in need thereof, such as for the treatment of plaque psoriasis. The present invention also relates to a process for preparing the composition and a suitable container system for administration of the composition. Preferably, the invention relates to the topical administration of betamethasone dipropionate and calcipotriene with one or more pharmaceutically acceptable excipients and propellants where the composition is stable in the container system coated with a coating material selected from the group comprising of epoxyphenol resin, modified polyesters, microflex coating or polyacrylates. | 2021-07-01 |
20210196632 | MODIFIED PLANT MESSENGER PACKS AND USES THEREOF - Disclosed herein are compositions including a plurality of plant messenger packs, (e.g., including a plant extracellular vesicle (EV), or segment, portion, or extract thereof), that are modified to have enhanced cell uptake (e.g., animal plant cell uptake, bacterial cell uptake, or fungal cell uptake), e.g., for use in a variety of agricultural or therapeutic methods. | 2021-07-01 |
20210196633 | CNS DELIVERY OF MRNA AND USES THEREOF - The present invention provides, among other things, methods and compositions for effective delivery of messenger RNA (mRNA) to the central nervous system (CNS). In particular, the present invention provides methods and compositions for administering intrathecally to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome, such that the administering of the composition results in the intracellular delivery of mRNA in neurons in the brain and/or spinal cord. The present invention is particularly useful for the treatment of CNS diseases, disorders or conditions, such as spinal muscular atrophy. | 2021-07-01 |
20210196634 | IN SITU GELIFYING POWDER - The object of the present invention is a composition in powder form comprising the following polysaccharides alginic acid or sodium alginate,—pectin, chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder. The process for preparing said powder by an atomization process and its use in the treatment of cutaneous wounds and in the sector of food preservation are additional objects of the invention. Moreover, additional objects of the invention are the composition in the form of solution or liquid suspension that represents the starting material to obtain said powder and the process for preparing said liquid composition. | 2021-07-01 |
20210196635 | DRUG-CONTAINING PARTICLE - The present invention provides a method of efficiently manufacturing drug-containing particle which has a sharp peak in the particle size distribution, is highly spherical, and good in fluidity. The present invention relates to a manufacturing method of a drug-containing particle, the drug-containing particle comprising a raw material particle and a coating layer on the outside of the raw material particle, the raw material particle and/or the coating layer comprising at least one drug, wherein the manufacturing method comprises a granulation process that agitates a mixture comprising a core particle for powder coating formed by coating the raw material particle with a polymer and a drug and/or pharmaceutically acceptable additive while spraying a solvent which can dissolve the polymer on the mixture. | 2021-07-01 |
20210196636 | PROCESS FOR PRODUCING A PHARMACEUTICAL COMPOSITION CONTAINING MICRO PARTICLES - A pharmaceutical composition having consistently a desirable release rate is prepared by controlling the finally mixing time based on the molecular weight measured in the intermediate product. The pharmaceutical composition includes micro particles containing a polyhydric alcohol, a salt, a water-soluble polymer and a pharmaceutically active ingredient. The micro particles are dispersed in a matrix of a hydrophobic ingredient and an amphipathic ingredient. | 2021-07-01 |
20210196637 | Compressible Cannabinoid Pharmaceutical Composition - A compressible pharmaceutical composition comprising a cannabinoid and at least one excipient is disclosed. The composition may be an intermediate used in the manufacture of compressible dosage forms of cannabinoids such as tablets. The cannabinoid may be CBD or THC. The compressible excipient may be a material such as microcrystalline cellulose or lactose, or a matrix forming polymer such as a polyvinylpyrrolidone-vinyl acetate copolymer; a polyvinylcaprolactam, polyvinyl acetate, and polyethylene glycol 6000 copolymer; and an ethylene oxide and propylene oxide copolymer. Also disclosed are dry granulation processes for manufacturing the inventive composition, including slugging, roller compaction, hot-melt extrusion, and melt granulation. | 2021-07-01 |
20210196638 | ORAL DRUG DOSAGE FORMS HAVING A DESIRED PK PROFILE AND METHODS OF DESIGNING AND PRODUCING THEREOF - The present disclosure, in some aspects, is directed to methods of designing an oral drug dosage form formulated and configured to have a desired pharmacokinetic profile. In other aspects, the present disclosure is directed to oral drug dosage forms having a desired pharmacokinetic profile, and methods of making, such as three-dimensional printing, such oral drug dosage forms. | 2021-07-01 |
20210196639 | THERAPEUTIC PREPRARTION COMPRISING INSULIN FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 2021-07-01 |
20210196640 | HARD CAPSULE HAVING IMPROVED HARDNESS, AND METHOD FOR MANUFACTURING SAME - An object of the present invention is to improve the hardness of the capsule film of a hard capsule. The present invention improves the hardness of the capsule film of a hard capsule by adding a starch decomposition product, and/or at least one clay mineral selected from the group consisting of talc, bentonite, and kaolin, to a hard capsule film. | 2021-07-01 |
20210196641 | Soft Capsule Film Composition - A soft capsule film composition, comprising: (A) a native gellan gum; (B) one or more hydrophilic polysaccharides; (C) a starch or modified starch; (D) a plasticizer; and (E) water, wherein a gelling agent other than the native gellan gum and the one or more hydrophilic polysaccharides is not an essential component. The soft capsule film composition shortens drying time at room temperature, suppresses the stickiness of the surface of a film sheet, imparts film sheet strength which can withstand continuous production in factory manufacturing with a rotary die filling machine or the like, and enables the manufacture of a good soft capsule with high adhesiveness. For this reason, the soft capsule produced using the soft capsule film composition can be utilized for various uses such as drugs, quasi drugs, cosmetics, and foods. | 2021-07-01 |
20210196642 | BULK ENTERIC CAPSULE SHELLS - The present disclosure relates to aqueous composition comprising hydroxypropyl methyl cellulose acetate succinate (HPMCAS) polymer dispersed in water, wherein the dispersed polymer is partially neutralized with at least one alkaline material. The instant disclosure also relates to compositions for use in methods of making capsule shells endowed with bulk enteric properties. The present disclosure also relates to capsules made according with the compositions and methods of the present disclosure. | 2021-07-01 |
20210196643 | PRODUCT - The invention provides an enteric dosage form comprising a live biotherapeutic product. | 2021-07-01 |
20210196644 | CANNABINOID COATED NANO-CAPSULES - One of the main problems with introducing target therapeutics and diagnostic biomarkers (Target substances) into the brain is the nearly impenetrable blood brain barrier. Some of the proposed described solutions to mobilizing these target therapeutics and markers into select areas of the brain include nano-particles and nano-capsules containing at least one of the target substances with exposed cannabinoid functional end groups that can selectively facilitate nano-capsule traversal across the blood brain barrier into brain tissue. In this way, the target substances can reach their intended target within the brain to either treat or identify regions of pathology. Certain concepts described involve nano/micro-particles with exposed cannabinoid functional end groups extending beyond the surface of the nano-particles. | 2021-07-01 |
20210196645 | TREATMENT OF COVID-19 - This disclosure relates to the use of an oxygen-containing liquid for treating a coronavirus infection, such as Covid-19. | 2021-07-01 |
20210196646 | IMPROVED FORMULATIONS FOR PANCREATIC ISLET ENCAPSULATION - Provided herein according to embodiments of the present invention is a microcapsule comprising: (a) one or more live mammalian pancreatic islet cells; and (b) an alginate composition encapsulating said islet cells, wherein said alginate composition comprises extracellular matrix proteins solubilized or suspended therein. Compositions comprising a plurality of the microcapsules and the use thereof in treating type I diabetes are also provided. | 2021-07-01 |
20210196647 | PHARMACEUTICAL COMPOSITION - The invention provides a pharmaceutical composition comprising activated carbon particles, for oral administration. The pharmaceutical composition may be for (use in) the treatment of gastrointestinal fistula. | 2021-07-01 |
20210196648 | DRUG-CONTAINING MULTILAYER FILM AND METHOD FOR FORMING THE SAME - A drug-containing multilayer film provided. The drug-containing multilayer film includes: a drug-containing layer; and an anti-adhesion layer on a surface of the drug-containing layer. The drug-containing layer is composed of a first composition including a first polymer material and a drug, and the first polymer material includes at least one selected from the group consisting of: polylactic acid (PLA) and polyethylene glycol (PEG), and the weight ratio of the first polymer material to the drug is about 1:0.01-0.3. The anti-adhesion layer is composed of a second composition, and the second composition includes a second polymer material, and the second polymer material includes at least one selected from the group consisting of polylactic acid and polyethylene glycol. | 2021-07-01 |
20210196649 | PATCH FOR ALLEVIATION AND PREVENTION OF ACNE - Proposed is a patch for the alleviation and prevention of acne, in which anti-acne activity of a biodegradable metal represented by Mg | 2021-07-01 |
20210196650 | SYSTEMS COMPRISING A COMPOSITE BACKING AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION - Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided. | 2021-07-01 |
20210196651 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY - The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs). | 2021-07-01 |
20210196652 | USE OF CYSTEAMINE AND DERIVATIVES THEREOF TO TREAT DYSFUNCTIONAL TEAR SYNDROME (DTS) - Methods for treating or inhibiting dysfunctional tear syndrome (DTS) or symptoms associated therewith, and compositions for use in the methods. | 2021-07-01 |
20210196653 | Delivery Of Esketamine For The Treatment Of Depression - The present invention provides devices and methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine. | 2021-07-01 |
20210196654 | METHOD OF TREATING CONDITIONS - The present invention provides a method for safe and efficacious administration of esketamine. | 2021-07-01 |
20210196655 | COMPOSITION FOR CROSS TALK BETWEEN ESTROGEN RECEPTORS AND CANNABINOID RECEPTORS - A composition for cross talk between estrogen receptors and cannabinoid receptors including a chelator and a receptor ligand is provided. A method of synthesizing the composition is also provided, and the composition may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging. | 2021-07-01 |
20210196656 | CASPASE INHIBITOR-CONTAINING DRUG FOR TREATING OR PREVENTING DISORDERS CAUSED BY TGF- , AND APPLICATIONS THEREOF - Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-β (TGF-β) signals and/or mitochondrial abnormalities in corneal endothelial cells. The present invention provides a drug which includes caspase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-β signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy. | 2021-07-01 |
20210196657 | SAFINAMIDE FOR TREATING MYOTONIA - The present invention relates to safmamide or a pharmaceutically acceptable salt thereof for use in the treatment of a condition caused by pathological sarcolemma hyperexcitability, and/or of any other condition in which the restoration of normal sarcolemma excitability may produce a therapeutic benefit or improvement, wherein said condition is preferably a myotonic disorder. | 2021-07-01 |
20210196658 | BETA-HYDROXYBUTYRATE MIXED SALT COMPOSITIONS AND METHODS OF USE - Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients. | 2021-07-01 |
20210196659 | THERAEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES - The present disclosure provides for treating neurodegenerative diseases comprising administering leucine, acetyl-leucine or a pharmaceutically acceptable salt thereof. | 2021-07-01 |
20210196660 | METHOD OF INHIBITING THE PROLIFERATION OF T AND/OR B LYMPHOCYTES VIA DIMETHYLARGININE DERIVATIVES AND LYMPHOCYTES PROLIFERATION INHIBITOR - The present invention belongs to the technical field of immunotherapy. A method of using dimethylarginine derivatives to inhibit the proliferation of lymphocyte. ADMA, SDMA, and their derivative DMGV can inhibit T cells and/or B cells proliferation in vitro by inducing mitochondrial ROS. ADMA and SDMA can induce mitochondrial ROS generation by the action of alanine-glyoxylate aminotransferase 2 (AGXT2), which converts both ADMA and SDMA into dimethylguanidino valeric acid (DMGV) in the mitochondria. The dimethylarginine dimethylamino hydrolase (DDAH) inhibitor PD404182 also inhibits T cell proliferation by allowing more ADMA and SDMA to be converted to DMGV. As a clinical relevance, DMGV effectively treated arthritis in mice which was caused by activated T cells. | 2021-07-01 |
20210196661 | METHOD FOR AMELIORATION OF INSULIN RESISTANCE - A method is disclosed utilizing the administration of extended release L-tri-iodothyronine in order to ameliorate insulin resistance. In other embodiments extended release L-tri-iodothyronine is combined with a biguanide and/or a thiazolidinedione and/or an inhibitor of the endoplasmic reticulum integrated stress response to provide a multi-targeted and synergistic approach to ameliorate insulin resistance. | 2021-07-01 |
20210196662 | ORAL COMPOSITION WITH IMMUNOMODULATING EFFECT ON NATURAL KILLER CELLS - A method of treating recurrent spontaneous abortions or repeated implantation failures in a human female subject, comprising providing a composition including a combination of fatty acids or esters thereof as the active ingredients, wherein the human female subject has at least 12% of peripheral blood NK cells in total peripheral blood cells, and/or the cytotoxicity of the peripheral blood NK cells is at least 10% higher than a mean cytotoxicity of a control population of healthy human females of reproductive age without a reproductive failure and who have given birth to at least one child; orally administering the composition for 15 to 70 days, wherein the total amount of fatty acids or esters, administered per day, is from 0.03 g/kg 1 g/kg of body weight, calculated as fatty acids so as to reduce an immune-mediated sub-fertility for the human female subject. | 2021-07-01 |
20210196663 | COMBINATION THERAPY COMPRISING AN OMEGA-3 FATTY ACID, A FOLATE SPECIES AND A VITAMIN B12 SPECIES - The present invention provides a combined therapy comprising the use of one or more omega-3 fatty acids and one or more B vitamins and for treating cognitive impairment, such cognitive impairment disorders include, especially but not exclusively, Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD). The present invention also provides a treatment for individuals suffering from cognitive impairment disorders that occur as a result of brain or cerebral atrophy, the invention includes inter alia methods of treating and/or reducing progression of brain atrophy and pharmaceutical compositions and nutritional supplements therefor. | 2021-07-01 |
20210196664 | HIGH PENETRATION PRODRUG COMPOSITIONS OF RETINOIDS AND RETINOIDS-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 2021-07-01 |
20210196665 | CCL5 Inhibitors - Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5. | 2021-07-01 |
20210196666 | Compounds For Inhibiting Secretory Leukocyte Protease Inhibitor (SLPI) - This invention relates to compounds that are useful for inhibiting the secretion of secretory leukocyte protease inhibitor (SLPI) in a subject. Methods of inhibiting metastasis of cancer and methods of treating cancer in a subject are also provided. | 2021-07-01 |
20210196667 | ESTROGEN RECEPTOR LIGANDS, COMPOSITIONS AND METHODS RELATED THERETO - Provided are compounds and methods for treating neurodegenerative diseases and conditions, such as multiple sclerosis, using an estrogen receptor-β ligand (ERβ ligand). | 2021-07-01 |
20210196668 | TIGLIEN-3-ONE DERIVATIVES - The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment | 2021-07-01 |
20210196669 | CANNABIS-BASED COMPOSITIONS FOR THE TREATMENT OF AUTISTIC SPECTRUM DISORDERS - Provided are therapeutic products and methods applicable to the treatment of patients with autistic spectrum disorder (ASD) or partial symptoms of ASD, said the products and methods using certain cannabis-based compositions enriched in CBD with a minimum content of THC under specific regimens and types of administration. | 2021-07-01 |
20210196670 | ORAL FORMULATIONS OF LAVENDER AND CANNABINOIDS - Described herein are cannabinoid formulations in combination with lavender and/or a lavender extract for oral administration. Further described herein are methods for orally administering one or more cannabinoids to a subject in need thereof and manufacturing oral formulations as described herein. | 2021-07-01 |
20210196671 | COMPOSITIONS COMPRISING 3'-O-METHYL-4'-O-SULFATE EPICATECHIN AND THERAPEUTIC USES OF SUCH COMPOSITIONS - Compositions can comprise the catechin metabolite 3′-O-methyl-4′-O-sulfate epicatechin. In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body, for example by administering the composition to an individual having or at risk of high blood pressure or a cardiovascular disease. In some embodiments, the compositions are used for weight maintenance or weight loss. In further embodiments the compositions are used for treating or preventing gestational diabetes mellitus. The compositions may be administered orally as a food product in which the 3′-O-methyl-4′-O-sulfate epicatechinis present in a concentration of at least 0.01 mg/g of the food product. | 2021-07-01 |
20210196672 | COMPOSITIONS COMPRISING 3'-O-METHYL-5-O-SULFATE EPICATECHIN AND THERAPEUTIC USES OF SUCH COMPOSITIONS - Compositions can comprise the catechin metabolite 3′-O-methyl-5-O-sulfate epicatechin. In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body, for example by administering the composition to an individual having or at risk of high blood pressure or a cardiovascular disease. In some embodiments, the compositions are used for weight maintenance or weight loss. In further embodiments the compositions are used for treating or preventing gestational diabetes mellitus. The compositions are preferably administered orally as a food product in which the 3′-O-methyl-5-O-sulfateepicatechinis present in a concentration of at least 0.01 mg/g of the food product. | 2021-07-01 |
20210196673 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING RESPIRATORY VIRAL INFECTIONS USING GREEN TREE EXTRACT - Modified green tea polyphenol compositions and their methods of use in treating and preventing SARS-CoV-2 infections are provided. An exemplary green tea polyphenol composition includes (−)-epigallocatechin-3-gallate that can be esterified with a C | 2021-07-01 |
20210196674 | Therapeutics for Malaria - The present disclosure describes a composition and method for treating and preventing malaria. The disclosure describes a peroxybioflavonoid composition comprising an artemisinin compound and one or more bioflavonoid compounds. | 2021-07-01 |
20210196675 | USE OF GINKGO BILOBA TERPENE LACTONE IN PREPARATION OF DRUGS FOR PREVENTION AND/OR TREATMENT OF TREMORS AND HEALTHCARE PRODUCTS - A use of one or more of a | 2021-07-01 |
20210196676 | TREATMENT OF VIRAL INFECTIONS AND VIRALLY ASSOCIATED LESIONS WITH SEQUITERPENE LACTONES - The present disclosure relates to the use of the sequiterpene lactones and Helenalin (H. tox) or its derivatives to treat viral infection and virally induced lesions, such as warts or wart-associated skin or mucosal lesion. A topical application, optionally using a skin covering such as gauze, a bandage, or a patch, can substantially reduce and even eliminate persistent, recurrent and/or treatment-resistant warts. | 2021-07-01 |
20210196677 | METHOD OF PREVENTING OR IMPROVING UV-INDUCED SKIN DAMAGE USING HYDROANGENOL AS ACTIVE INGREDIENT - Provided is a method for preventing or improving UV-induced skin damage of a subject in need thereof, which comprises administering to the subject an effective amount of a composition containing hydrangenol derived from the extract of | 2021-07-01 |
20210196678 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF - This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject. | 2021-07-01 |
20210196679 | MATERIALS AND METHODS FOR IMPROVING GASTROINTESTINAL FUNCTION - The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity. | 2021-07-01 |
20210196680 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK - The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I); | 2021-07-01 |
20210196681 | SELECTIVE PRESENILIN-2 GAMMA-SECRETASE INHIBITORS - The present invention relates to selective presenilin-2 γ-secretase inhibitors for use in the treatment of various diseases associated with a defect leading to Notch receptor hyperactivity. In particular the present invention relates to selective presenilin-2 γ-secretase inhibitors for use as a highly selective anti-cancer treatment. Preferred selective presenilin-2 γ-secretase inhibitors include small molecules, like 4-aminoquinolines or imidazole compounds, (monoclonal) antibodies and known γ-secretase inhibitors or analogues and combinations thereof. | 2021-07-01 |
20210196682 | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMPOUND PREPARATION COMPRISING GLUCOKINASE ACTIVATOR AND DPP-IV INHIBITOR, AND PREPARATION METHOD AND USE THEREOF - Disclosed is a pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof, and a DPP-IV inhibitor. Disclosed are a pharmaceutical composition and a fixed dose of a compound preparation, and the methods for preparing the pharmaceutical composition and the fixed dose of the compound preparation and the uses thereof. | 2021-07-01 |
20210196683 | PHARMACEUTICAL COMBINATION AND COMPOSITION, AND COMBINATION PREPARATION CONTAINING GLUCOKINASE ACTIVATOR AND BIGUANIDE HYPOGLYCEMIC DRUG AS WELL AS PREPARATION METHOD AND USE THEREOF - A pharmaceutical combination. The pharmaceutical combination contains a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic marker thereof, a crystalline form thereof, a hydrate, a solvate, a diastereoisomer or an enantiomer form, and a biguanide hypoglycemic drug. A pharmaceutical composition and a fixed dose combination preparation as well as a preparation method and use of the pharmaceutical composition and the fixed dose combination preparation. | 2021-07-01 |
20210196684 | 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE - The present invention generally relates to 6-amino-2,4-dihydropyrano[2,3-c] pyrazoles as a ubiquitin specific protease 7 (USP7) inhibitor useful for the treatment of diseases mediated by malfunction of USP7, such as inflammation, cancer, and immunological disorders. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases mediated by malfunction of USP7, in mammals using compounds disclosed herein. | 2021-07-01 |
20210196685 | COMPOSITION FOR ERADICATING HELICOBACTER PYLORI - The present invention relates to a composition for eradicating | 2021-07-01 |
20210196686 | SYNERGISTIC NUTRITIONAL COMPOSITIONS FOR ENHANCING ATP EFFICIENCY - The invention disclosed herein relates to synergistic nutritional compositions for enhancing cellular ATP efficiency. Particularly, the invention relates to a synergistic, efficient, nutritional composition for promoting cellular ATP production comprising a therapeutically active exogenous combination of a stabilized oxaloacetate and a biotin-manganese complex along with pharmaceutically acceptable excipients; wherein the stabilized oxaloacetate and the biotin-manganese or salts thereof are present in a weight ratio ranging from 1:0.01 to 1:0.2. Further, the present synergistic nutritional composition is useful for treating ATP deficiency disorders, age-related metabolic disorders, neurodegenerative diseases, cardiovascular diseases, bone related disorders, central nervous system diseases, cognitive disorders and like thereof. | 2021-07-01 |
20210196687 | Promotion of Epithelial Repair - There is provided a method for promoting epithelium repair in a subject, the method comprising administering to the subject a therapeutically effective amount of an activator of PI3K/Akt signalling. | 2021-07-01 |
20210196688 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS - Methods of treatment comprising administering a compound having structure (I), | 2021-07-01 |
20210196689 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS - Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed. | 2021-07-01 |
20210196690 | OCULAR FORMULATIONS FOR DRUG-DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE - The present invention relates to topical formulations comprising a compound of the following formula: | 2021-07-01 |
20210196691 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS - The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof. | 2021-07-01 |
20210196692 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF - Provided herein is an amorphous compound represented by Formula (I): | 2021-07-01 |
20210196693 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-- 3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA - Provided herein are low impurity compositions comprising a compound represented by Formula (I): | 2021-07-01 |
20210196694 | MUSCLE REGENERATION - The invention provides anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopa-thy, as well as a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providing the subject with a therapeutically effective amount of an elastase inhibitor. Further provided is a pharmaceutical composition comprising anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy. Elastase inhibitors may have a protective effect on muscle progenitor cells and their regenerative potential, which aids muscle cell regeneration. By protecting regenerative potential of muscle progenitor cells, elastase inhibitors enable or enhance the grown of new or existing muscle fibres. | 2021-07-01 |
20210196695 | K-RAS MODULATORS - Provided herein, inter alia, are methods and compounds for inhibiting K-Ras and for treating cancer. | 2021-07-01 |
20210196696 | DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR - The present invention relates to methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for at least two five-consecutive day cycle, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles; the use of said compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease administered in accordance with said dosage regimen; therapeutic regimen comprising administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof. | 2021-07-01 |
20210196697 | COMBINATION THERAPIES FOR TREATING BIPOLAR DISORDER AND ADHD, AND METHODS FOR USING THE SAME - The present invention relates to pharmaceutical combinations and compositions, and methods of using the same for treatment of attention deficit hyperactivity disorder (ADHD) and bipolar disorder (BD). The invention relates to combination therapies for the treatment of BD and for ADHD, and methods for treating BD and ADHD using such therapies. The present invention also relates to methods of determining an optimal combination drug treatment therapy for BD and for ADHD, methods of optimizing a combination drug treatment therapy for BD and for ADHD, methods of optimizing dosage of a drug in a combination drug treatment therapy for BD and for ADHD, as well as methods for monitoring the efficacy of a combination therapy for the treatment of BD and for ADHD. The present invention involves analyzing the membrane potential of cells isolated from a BD patient treated with the combination therapy and from an ADHD patient treated with the combination therapy, and calculating a membrane potential ratio therefrom. | 2021-07-01 |
20210196698 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING LENALIDOMIDE - The present invention relates to pharmaceutical compositions comprising Lenalidomide. More particularly, the present invention relates to a stable composition comprising anhydrous Lenalidomide Form I and one or more pharmaceutically acceptable excipients and process for preparing such compositions. | 2021-07-01 |
20210196699 | CGRP ANTAGONISTS FOR TREATING MIGRAINE BREAKTHROUGH - Disclosed are methods of treating breakthrough migraine in patients using breakthrough CGRP antagonists. Also disclosed are methods for the prophylactic treatment of migraine. | 2021-07-01 |
20210196700 | NICOTINE FORMULATION - The invention relates to a pharmaceutical formulation comprising nicotine. The formulation can be aerosolised at ambient temperature for delivery via inhalation. The invention also relates to a method of delivering nicotine to a subject via inhalation, and specifically via the use of a nebuliser. | 2021-07-01 |
20210196701 | INHIBITING MUTANT IDH-1 - Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA). | 2021-07-01 |
20210196702 | TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS - Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent VMAT2 inhibitor (+)α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol ((+)α-HTBZ) is used in the methods described herein for treating a subject in need thereof. | 2021-07-01 |
20210196703 | COMPOSITIONS OF BUPRENORPHINE AND ANTAGONISTS - The invention relates to a composition comprising buprenorphine and a μ opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; | 2021-07-01 |
20210196704 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and/or to enhance dextromethorphan plasma levels. | 2021-07-01 |
20210196705 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-07-01 |
20210196707 | Stable Oral Liquid Formulation of Trimetazidine - Disclosed is a stable oral liquid pharmaceutical composition of trimetazidine having a pH of about pH 4 to about pH 8, comprising a therapeutically effective amount of trimetazidine or a pharmaceutically acceptable salt thereof, one or more orally acceptable buffers, and one or more orally acceptable preservatives that is effective in said pH range. Also disclosed are methods of treating patients with stable oral liquid pharmaceutical composition. The phamaceutical composition is particularly suitable for treating a patient having a condition treatable by trimetazidine, such as cirrhosis and renal deficiency, and who has a decreased tolerance for acidic or highly basic oral solutions. | 2021-07-01 |
20210196708 | Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazi- ne and salts thereof - A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(pheny)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain. | 2021-07-01 |
20210196709 | ARIPIPRAZOLE SUSTAINED-RELEASE MICROSPHERE AND PREPARATION METHOD THEREFOR - The present invention provides an aripiprazole sustained-release microsphere and a preparation method therefor. The microsphere comprises aripiprazole and polylactide-glycolide. The microsphere is of a spherical reticular skeleton structure, with reticular micropores distributed in the spherical surface, and aripiprazole filled in the micropores. The average particle diameter of the microsphere is less than 20 μm, and is suitable for a 5 gauge needle. The content of aripiprazole is 65%-80% of the total weight of the microsphere. | 2021-07-01 |
20210196710 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR - This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof. | 2021-07-01 |
20210196711 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS - Disclosed herein are methods for treating or preventing myeloproliferative neoplasms in a subject in need thereof, and for effecting specific clinically relevant endpoints, comprising administering a therapeutically effective amount of an LSD1 inhibitor. | 2021-07-01 |
20210196712 | METHODS OF TREATING COCHLEAR SYNAPTOPATHY - The present application describes the use of gamma secretase inhibitors and gamma secretase modulators for the treatment of cochlear synaptopathy. | 2021-07-01 |
20210196713 | SMALL MOLECULE INHIBITORS OF CANCER STEM CELLS AND MESENCHYMAL CANCER TYPES - The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin. | 2021-07-01 |
20210196714 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH ABERRANT RAS/MAPK SIGNALING - This invention relates generally to methods for treating, preventing and/or ameliorating symptoms of disorders characterized with aberrant RAS/MAPK signaling (e.g., Kabuki Syndrome). This invention further relates to methods and compositions for treating such disorders with pharmaceutical compositions capable of one or more of inhibiting aberrant RAS/MAPK signaling, inhibiting MEK hyperactivation related to RAS/MAPK signaling, inhibiting aberrant kmt2d, kmd6a, RAP1A, and/or RAP1B activity and/or expression related to RAS/MAPK signaling, preventing diminished RAF1 inhibition of RAP1A or RAP1B activity within RAS/C MAPK signaling, preventing or ameliorating symptoms of disorders characterized with aberrant RAS/MAPK signaling. | 2021-07-01 |
20210196715 | Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension - The present invention relates to high doses of macitentan, i.e. propylsulfamic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof, or of aprocitentan, for use in the treatment and/or prevention of pulmonary arterial hypertension (PAH). Moreover, the present invention relates to the use of high doses of macitentan, or of aprocitentan, for the manufacture of a medicament for the treatment and/or prevention of PAH, as well as to a method for the treatment and/or prevention of PAH comprising high doses of macitentan or of aprocitentan. Further, the present invention relates to a dosage regimen for the treatment and/or prevention of PAH as well as to a combination of macitentan, or of aprocitentan, with one or more phosphodiesterase type 5 (PDE5) inhibitors, prostacyclin analogues, prostacyclin receptor agonists or soluble guanylate cyclase stimulators. Therein, PAH is preferably mild or moderate PAH. Moreover, the present invention relates to a pharmaceutical composition for the treatment of PAH comprising a high dose of macitentan or of aprocitentan. | 2021-07-01 |
20210196716 | COMPOSITIONS AND METHODS FOR TREATING EYE DISORDERS - Provided herein are compositions and methods for treating eye disorders. In particular, provided herein are neuroprotective compositions and methods for treating vision loss and related disorders. | 2021-07-01 |
20210196717 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF - Peptides, peptidomimetics and small molecules, collectively referred to as “decoy peptides”, are provided, which interfere with binding to a TIR domain of a toll-like receptor 4 (TLR4), and inhibit a TLR4-induced signaling pathway. These decoy peptides may be useful for treating diseases associated with induction of TLR4 signaling pathway such as a disease or disorder secondary to a cardiovascular disease, sepsis or an inflammatory disease. | 2021-07-01 |
20210196718 | ANTIVIRAL DRUG COMPOUNDS AND COMPOSITION THEREOF - The present invention relates to compounds and pharmaceutical composition having antiviral effects. Over 1200 molecules were screened and 55 molecules having statistically significant anti-HIV activity were identified and selected. The compound Methotrexate (MTX-HYD) and its analogues, the combinations thereof and their combination with other anti-retrovirals were selected for repurposing the compounds as anti-HIV drugs. The present invention may further relate to pharmaceutical composition comprising compounds in combination with active drugs having anti-HIV activity. | 2021-07-01 |
20210196719 | USE OF CDK4/6 INHIBITOR IN COMBINATION WITH EGFR INHIBITOR IN THE PREPARATION OF MEDICAMENT FOR TREATING TUMOR DISEASES - Provided in the present invention is a use of CDK4/6 inhibitor in combination with EGFR inhibitor in the preparation of a medicament for treating tumor diseases. In particular, provided in the invention is a use of a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) in combination with a human epidermal growth factor receptor inhibitor (EGFRi) for the preparation of a medicament for preventing or treating tumor diseases. | 2021-07-01 |
20210196720 | USE OF VIBEGRON TO TREAT PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME - The present disclosure is directed to a method of treating or preventing pain associated with irritable bowel syndrome comprising orally administering to a subject in need thereof vibegron. | 2021-07-01 |
20210196721 | Stable Pharmaceutical Formulations of Pemetrexed - The present invention relates to a long term storage stable multi-dose ready-to use or ready-to dilute pharmaceutical liquid formulation comprising pemetrexed or a pharmaceutically acceptable salt thereof, an antioxidant, a preservative, a buffering agent, and a pharmaceutically acceptable fluid. The invention also relates to a process of preparing the formulation, a kit and a method of treatment of patients having lung cancer by administering the pharmaceutical formulation to a subject in need thereof. | 2021-07-01 |
20210196722 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases. | 2021-07-01 |
20210196723 | Modulators of DUX4 for Regulation of Muscle Function - Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell-based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases. | 2021-07-01 |
20210196724 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE - The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders. | 2021-07-01 |
20210196725 | TREATMENT OF RELAPSED FOLLICULAR LYMPHOMA - Provided herein are methods treating follicular lymphoma (FL) in subjects having early disease progression after immunochemotherapy using a phosphoinositide-3-kinase (PI3K) inhibitor. In certain embodiments, the methods comprise treating FL in subjects having disease progression within 24 months of initiating first-line or subsequent immunochemotherapy using a phosphoinositide-3-kinase (PI3K) inhibitor. | 2021-07-01 |